Neurizon Therapeutics Limited (NUZTF) Shareholder/Analyst Call Transcript
Neurizon Therapeutics Limited (NUZTF) Shareholder/Analyst Call October 8, 2026 1:00 AM EDT
Company Participants
Chris-Carol Bremer – Chief Executive Officer
Sergio Duchini
Dan OConnell – Chief Financial Officer
Presentation
Unknown Attendee
We are recording this important conversation today as Neurizon enters an important phase of its development. [indiscernible] platform trial. Top line results are expected in Q2 2027 and Dr. Chris Bremer has joined the company as Chief Executive Officer. Welcome, Chris.
Chris-Carol Bremer
Chief Executive Officer
Thank you.
Unknown Attendee
Today, we’ll get to know Chris and discuss the broader Neurizon story. We’ll look at the science, the clinical program. We’ll look at manufacturing and regulatory foundations, global partnerships, leadership capability and strategic opportunities that have been built around NUZ-001.
Question-and-Answer Session
Unknown Attendee
So Chris, I might turn to you first. For people meeting you for the first time, what shaped your career in biotechnology, and what attracted you to Neurizon at this particular point in its development?
Chris-Carol Bremer
Chief Executive Officer
I don’t want to bore you with too much detail, but I think what a good summary of my career is it was always the part of translation of science to commercial. And a big part of that career was more on the commercial side, but they always wanted a leader who understands the science well. And then in the second part, they really positioned me in that gap of science and commercial where you need to get late-stage clinical trials right to translate it into the best value for patients and also for shareholders.
And to be honest, many times, it’s the same thing because we need to reach as many patients as possible and that then automatically translates to value. And to be honest, I’ve always very much enjoyed that part. I’m a physician, I like the science, but I like
